Adefovir-associated HIV-1 RT mutation K70E in the age of tenofovir

被引：0
|
作者：
Kagan, R
Ross, L
Winters, M
Merigan, T
Heseltine, P
Lewinski, M
机构：
[1] Quest Diagnost Nichols Inst, San Juan Capistrano, CA USA
[2] GlaxoSmithKline Inc, Res Triangle Pk, NC USA
[3] Stanford Univ, Ctr AID Res, Stanford, CA 94305 USA
来源：
ANTIVIRAL THERAPY | 2005年 / 10卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：S103 / S103
页数：1
相关论文
共 50 条
  • [31] Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethyl]adenine in vitro
    Cherrington, JM
    Mulato, AS
    Fuller, MD
    Chen, MS
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (09) : 2212 - 2216
  • [32] Structures of HIV-1 RT-DNA complexes before and after incorporation of the anti-AIDS drug tenofovir
    Tuske, S
    Sarafianos, SG
    Clark, AD
    Ding, JP
    Naeger, LK
    White, KL
    Miller, MD
    Gibbs, CS
    Boyer, PL
    Clark, P
    Wang, G
    Gaffney, BL
    Jones, RA
    Jerina, DM
    Hughes, SH
    Arnold, E
    NATURE STRUCTURAL & MOLECULAR BIOLOGY, 2004, 11 (05) : 469 - 474
  • [33] HIV-1 RT mutations in patients after 24 weeks of tenofovir disoproxil fumarate (formerly PMPA prodrug) therapy
    Miller, MD
    Margot, NA
    Mills, R
    McGowan, I
    ANTIVIRAL RESEARCH, 2000, 46 (01) : A37 - A37
  • [34] Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination Antiretroviral therapy containing tenofovir
    von Wyl, Viktor
    Yerly, Sabine
    Boeni, Juerg
    Buergisser, Philippe
    Klimkait, Thomas
    Battegay, Manuel
    Bernasconi, Enos
    Cavassini, Matthias
    Furrer, Hansjakob
    Hirschel, Bernard
    Vernazza, Pietro L.
    Rickenbach, Martin
    Ledergerber, Bruno
    Guenthard, Huldrych F.
    CLINICAL INFECTIOUS DISEASES, 2008, 46 (08) : 1299 - 1309
  • [35] Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations
    Hayashida, Tsunefusa
    Hachiya, Atsuko
    Ode, Hirotaka
    Nishijima, Takeshi
    Tsuchiya, Kiyoto
    Sugiura, Wataru
    Takiguchi, Masafumi
    Oka, Shinichi
    Gatanaga, Hiroyuki
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (10) : 2760 - 2766
  • [36] Emergence of the H208Y mutation in the reverse transcriptase (RT) of HIV-1 in association with nucleoside RT inhibitor therapy
    Nebbia, G.
    Sabin, Caroline A.
    Dunn, D. T.
    Geretti, Anna Maria
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 59 (05) : 1013 - 1016
  • [37] Identification of RT mutations associated with HIV-1 drug resistance in treatment naive patients
    Magiorkinis, E
    Paraskevis, D
    Lazanas, M
    Kiosses, VG
    Gargalianos, P
    Hatzakis, A
    AIDS, 1998, 12 : S25 - S25
  • [38] Virtual Screening Models for Prediction of HIV-1 RT Associated RNase H Inhibition
    Poongavanam, Vasanthanathan
    Kongsted, Jacob
    PLOS ONE, 2013, 8 (09):
  • [39] Antiviral Activity of Tenofovir Alafenamide Against HIV-1 Subtypes and Emergence of K65R
    Cox, Stephanie
    Margot, Nicolas
    Miller, Michael
    Callebaut, Christian
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2018, 34 (05) : 456 - 458
  • [40] HUMAN-IMMUNODEFICIENCY-VIRUS-1 (HIV-1)-SPECIFIC REVERSE-TRANSCRIPTASE (RT) INHIBITORS MAY SUPPRESS THE REPLICATION OF SPECIFIC DRUG-RESISTANT (E138K)RT HIV-1 MUTANTS OR SELECT FOR HIGHLY RESISTANT (Y181C-]C181I)RT HIV-1 MUTANTS
    BALZARINI, J
    KARLSSON, A
    SARDANA, VV
    EMINI, EA
    CAMARASA, MJ
    DECLERCQ, E
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (14) : 6599 - 6603
12345